Is prostate‐specific antigen a potential new marker of androgen excess in polycystic ovary syndrome?

Vural, Bírol; Özkan, Sebiha; Bodur, Harika

doi:10.1111/j.1447-0756.2007.00507.x

Cited by 18 publications

(15 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our own previous study reported urinary PSA levels almost 200 fold higher in females with PCOS in comparison to controls (12). Vural et al reported serum PSA elevations in patients with PCOS (13), a finding confirmed by others (14–18). We have further documented that serum and urine PSA levels are highly elevated in female-to-male transsexuals after testosterone treatment, thereby demonstrating that androgens regulate PSA synthesis in female tissues in vivo (19, 20).…”

Section: Introductionsupporting

confidence: 61%

Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS)

Diamandis

Stanczyk

Wheeler

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background Polycystic ovarian syndrome (PCOS) is a common cause of reproductive and metabolic dysfunction. We hypothesized that serum prostate specific antigen (PSA) may constitute a new biomarker for hyperandrogenism in PCOS. Method We conducted a cross-sectional study of 45 women with PCOS and 40 controls. Serum from these women was analyzed for androgenic steroids and for complexed PSA (cPSA) and free PSA (fPSA) with a novel fifth generation assay with a sensitivity of ~10 fg/mL for cPSA and 140 fg/mL for fPSA. Results cPSA and fPSA levels were about 3 times higher in PCOS compared to controls. However, in PCOS, cPSA and fPSA did not differ according to hip-to-waist ratio, Ferriman-Gallwey score, or degree of hyperandrogenemia or oligo-ovulation. In PCOS and control women, serum cPSA and fPSA levels were highly correlated with each other, and with free and total testosterone levels, but not with other hormones. Adjusting for age, body mass index (BMI) and race, cPSA was significantly associated with PCOS, with an odds ratio (OR) of 5.67 (95% CI: 1.86, 22.0). The OR of PCOS for fPSA was 7.04 (95% CI: 1.65, 40.4). A multivariate model that included age, BMI, race and cPSA yielded an area-under-the-receiver-operating-characteristic (AUC-ROC) curve of 0.89. Conclusions Serum complexed PSA and free PSA are novel biomarkers for hyperandrogenism in PCOS and may have value for disease diagnosis.

show abstract

Section: Introductionsupporting

confidence: 61%

Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS)

Diamandis

Stanczyk

Wheeler

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…Vural et al . found elevated PSA levels in polycystic ovary syndrome, and thus it can be used as a useful androgen excess marker 8 …”

Section: Average Serum Levels Of Psa In Hyperandrogenic and Control Gmentioning

confidence: 95%

Prostate‐specific antigen levels as hyperandrogenism marker in women

Camacho

López-Elorza

Rodríguez-Rey

et al. 2009

Acad Dermatol Venereol

View full text Add to dashboard Cite

In conclusion, in our groups, statistically significant elevations of serum PSA levels were observed in women with clinical signs of hyperandrogenism. We found higher levels in ovarian and adrenal subtypes, whereas women without clinical hyperandrogenism or women with clinical hyperandrogenism and normal hormonal serum levels had lower PSA levels.Although more studies and wider sample groups are needed, it seems that PSA determination is a good clinical hyperandrogenism marker and could be used in the monitoring of anti-androgenic treatment.

show abstract

“…Increased serum androgens were causing an increase in serum PSA levels in these patients. In another study, significantly higher levels of serum PSA were found in hirsute women than in controls 34 . In our study, the maximum values of free PSA were higher in the patient group, however, there was not any statistically significant difference in PSA levels between the patient and control groups.…”

Section: Discussionmentioning

confidence: 84%

Serum prostate spesific antigen levels in women with androgenetic alopecia

Kurtoğlu¹,

Emre²,

Metin³

et al. 2019

TURKDERM

View full text Add to dashboard Cite

Amaç: Androgenetik alopesi (AGA) patogenezinde androjenlerin etkisi bilinmektedir. Çalışmalar ultrasensitif serum prostat spesifik antijen (PSA) analizinin hirsutizmli kadınlarda hiperandrojenizmin bir biyokimyasal belirteci olabileceğini göstermiştir. Bu nedenle AGA'lı kadınlarda serum PSA değerlerinin, androjenlerin hedef organlardaki etkisinin bir belirteci olarak kullanılabileceği düşünülmektedir. Bu çalışmanın amacı AGA'lı kadın hastalarda serum PSA düzeylerini araştırmaktır. Gereç ve Yöntem: Araştırma kapsamında toplam 100 AGA'lı kadın hasta ve 67 sağlıklı kadın gönüllü incelendi. Hastaların AGA tanısı öykü, dermatolojik muayene ve saç çekme testi ile konuldu. Hastalık şiddeti Ludwig evrelemesine göre sınıflandırıldı. Total ve serbest PSA "Roche Cobas e 601 immünoassay analizörde elektrokemilüminesans immünoassay" yöntemiyle çalışıldı. Bulgular: Çalışmaya alınan hastaların 29'unda (%29) Ludwig 1, 64'ünde (%64) Ludwig 2, 7'sinde (%7) Ludwig 3 düzeyinde AGA tespit edildi. Total testosteron hasta grubunda kontrol grubuna göre anlamlı olarak yüksek bulundu (p=0,03). Serbest PSA, total PSA, prolaktin, ferritin, kortizol, folikül uyarıcı hormonu, lüteinleştirici hormon, östradiol düzeyleri hem hasta hem de kontrol gruplarında normal sınırlar içindeydi ve her iki grup arasında anlamlı bir fark bulunmadı. Sonuç: Çalışmamızda AGA'lı kadın hastalar ve sağlıklı kontrol grubu arasında serbest PSA (p=0,084) ve total PSA (p=0,285) serum düzeyleri açısından anlamlı farklılık bulunmadı. Bu konuda geniş hasta gruplarında yapılacak çalışmalara ihtiyaç vardır. Anahtar Kelimeler: Prostat spesifik antijen, androgenetik alopesi, Ludwig Background and Design: The role of androgens in androgenetic alopecia (AGA) patogenesis is well known. Studies set forth that ultrasensitive serum prostate specific antigen (PSA) analysis could be a biochemical marker of hyperandrogenism in women with hirsutism. Serum PSA levels in women with AGA can be used as an indicator of the effect of androgens in target organs. The aim of this study was to investigate serum PSA levels in women with AGA. Materials and Methods: A total of 100 female patients and a voluntary group of 67 healthy women were evaluated in this research. The diagnosis of AGA was established through history, dermotological evaluation and hair pull test. The degree of hair loss was categorized using the Ludwig scale. Total and free PSA were measured by an "Roche Cobas e 601 immunoassay analyser using the electrochemiluminescence immunoassay" method. Results: Twenty-nine patients (29%) had Ludwig 1, 64 (64%) had Ludwig 2, and 7 (7%) had Ludwig 3 hair loss. Total testosterone level was significantly higher in patient group than in control group (p=0.03). The levels of free PSA, total PSA, prolactin, ferritin, cortisol, folliclestimulating hormone, luteinizing hormone, and estradiol were within the normal limits in both patient and control groups and there was no statistically significant difference between the groups (p>0.05). Conclusion: In our study, there was no statistically signif...

show abstract

Is prostate‐specific antigen a potential new marker of androgen excess in polycystic ovary syndrome?

Cited by 18 publications

References 39 publications

Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS)

Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS)

Prostate‐specific antigen levels as hyperandrogenism marker in women

Serum prostate spesific antigen levels in women with androgenetic alopecia

Contact Info

Product

Resources

About